Video

Dr. Jain on Increased Lymphocytosis Following Treatment With a B-Cell Receptor Inhibitor

Author(s):

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor for patients with chronic lymphocytic leukemia.

The initial pattern of response following treatment with a b-cell receptor inhibitor is rapid reduction in lymphadenopathy associated with increased lymphocytosis. When patients start idelalisib and this reaction occurs, a treating oncologist should not regard this as progression — it may take 6-9 months for the white blood cell count to normalize.

<<<

View more from the 2014 Chemotherapy Foundation Symposium

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.